ClinicalTrials.gg
CompletedNCT04056260Updated Nov 18, 2026

ICG-NIR Guided Lymph Node Dissection in Gastric Cancer

An interventional study of ICG-NIR guided surgery in Stomach Neoplasm, sponsored by Ho Seok Seo. Completed at 1 site in South Korea. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ho Seok Seo · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now CompletedFirst site in South Korea+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
219
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 522 studies in Stomach Neoplasms with a site in Korea, Republic of — 77 open to participants now, 116 under way, 20 of them phase 3. Stomach Neoplasms · Korea, Republic of.

Enrollment
123rd of 449
219 · median 95
Started
2022
with 30 others
No phase
104 of 522
21 open now
Registered
333rd of 522
by date

Among the 522 studies in Stomach Neoplasms with a site in Korea, Republic of, this one is the 123rd largest by enrollment of the 449 interventional ones that give a count, is one of 31 that started in 2022, is one of 104 with no phase, and was the 333rd registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

77 of the 522 studies in Stomach Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 522 studies in Stomach Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

As the survival rate of patients with gastric cancer has increased, there has been a growing interest in interventions that improve postoperative quality of life. Therefore minimally invasive surgery or endoscopic resection has been performed much more frequently. However, adequate lymph node dissection is important as well. The aim of the study is to identify the feasibility of indocyanine green - near infra-red (ICG-NIR) guided sentinel lymph node dissection for the treatment of gastric cancer.

03

Conditions studied

  • Stomach Neoplasm

Browse trials for

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • dignosed gastric adenocarcinoma
  • tumor: size 4cm or smaller
  • depth of invasion: mucosa, submucosa, proper muscle
  • candidates of laparoscopic radical gastrectomy

Exclusion criteria

Exclusion Criteria:

  • metachronous
  • number of tumors: 2 or more
  • remnant gastric cancer
  • indication for endoscopic resection
  • history of chemotherapy or radiation therapy
  • pregnancy
  • allergy to ICG
  • gastric cancer
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    ICG injection

    ICG 0.5mg/ml x 0.5ml x 4 sites

    Procedure: ICG-NIR guided surgery

Interventions

  • ProcedureICG-NIR guided surgery

    ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy

06

What researchers measure

Primary outcomes

  1. sensitivity and specificity

    sensitivity and specificity of ICG-NIR guided lymph node dissection

    Time frame: 1 month

07

Study locations

1 site
  • Seoul St. Mary's Hospital, The Catholic University of Korea
    Seoul, 06591, South Korea
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Aug 2022, 5 months.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's 5 months is below that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Mar 2020 → Mar 2022, primary completion Aug 2020 → Aug 2022 and completion Dec 2020 → Dec 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2019
First posted
Aug 14, 2019
StartActual
Mar 20, 2022was Mar 2020
Primary completionActual
Aug 31, 2022was Aug 2020
CompletionActual
Dec 31, 2022was Dec 2020
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 18, 2026
Sites
1 site added — first site in South Korea
Show site
  • Seoul St. Mary's Hospital, The Catholic University of Korea · Seoul, South Korea
Nov 18, 2026
Start date
Mar 20, 2020→Mar 20, 2022 (actual)
Nov 18, 2026
Primary completion
Aug 31, 2020→Aug 31, 2022 (actual)
Nov 18, 2026
Study completion
Dec 31, 2020→Dec 31, 2022 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Status unknown→Completed
    1 site added — first site in South Korea
    Show site
    • Seoul St. Mary's Hospital, The Catholic University of Korea · Seoul, South Korea
    Start date Mar 20, 2020→Mar 20, 2022 (now actual)
    Primary completion Aug 31, 2020→Aug 31, 2022 (now actual)
    Study completion Dec 31, 2020→Dec 31, 2022 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04056260
Lead sponsor
Ho Seok Seo
Responsible party
Ho Seok Seo (professor, Seoul St. Mary's Hospital) — Sponsor-investigator
First posted
Aug 14, 2019
Start date
Mar 20, 2022
Primary completion
Aug 31, 2022
Completion
Dec 31, 2022
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion